Cougar Biotechnology Announces Initiation Of Phase III Trial Of CB7630 (Abiraterone Acetate)

Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced that it has started enrolling patients in its Phase III clinical trial (COU-AA-301) of the Company’s lead drug candidate CB7630 (abiraterone acetate). The Phase III trial is a randomized, double-blind, placebo-controlled trial of CB7630 plus prednisone in patients with metastatic castration-resistant prostate cancer who have failed docetaxel-based chemotherapy.

More: continued here

Filed under: Prostate on May 15th, 2008